• Initiator Pharma will raise approximately DKK 8.2 million before costs through a directed issue of 5,913,170 shares to Klockhuset Investment.
• The subscription price is SEK 2.05 per share, with one warrant attached to each new share.
• Warrants exercisable at DKK 1.38961 through June 30, 2027, could raise an additional DKK 8.2 million.
• Shareholder dilution will total approximately 7.95% from the placement, rising to 14.73% upon full warrant exercise.
• Proceeds will support pudafensine partnering and IP2016 development; together with existing cash, funding is expected to cover operations into 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Initiator Pharma A/S published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.